Triple-Negative Breast Cancer: A-BRAVE Trial Results - Avelumab Immunotherapy Extends Overall Survival
The A-BRAVE trial, has shown that while 1 year of avelumab immunotherapy after standard treatment didn’t improve disease-free survival, it did significantly extend overall survival in high-risk early Triple-negative breast cancer (TNBC) patients. This is a significant finding as TNBC is notoriously aggressive and difficult to treat. What's everyone's take on this? Does this change the standard of care for TNBC or will this be limited to high-risk patients? Any insights on how this might impact future research or treatment options?
Triple-Negative Breast Cancer: A-BRAVE Trial Results - Avelumab Immunotherapy Extends Overall Survival
The A-BRAVE trial, has shown that while 1 year of avelumab immunotherapy after standard treatment didn’t improve disease-free survival, it did significantly extend overall survival in high-risk early Triple-negative breast cancer (TNBC) patients. This is a significant finding as TNBC is notoriously aggressive and difficult to treat. What's everyone's take on this? Does this change the standard of care for TNBC or will this be limited to high-risk patients? Any insights on how this might impact future research or treatment options?
Comments (4)
Great news but I'm not sure it should be standard of care for all TNBC patients until we see more evidence of its effectiveness across all risk levels.
This is really promising for high-risk TNBC patients. I wonder how soon we'll see this incorporated into standard treatment guidelines.
Great news but I'm not sure it should be standard of care for all TNBC patients until we see more evidence of its effectiveness across all risk levels.
As a TNBC survivor, this gives me hope. I wonder if this will help reduce the risk of recurrence for those of us who are high-risk.